Pharmexa obtains global license to Provax® from Biogen Idec
Jakob Schmidt, CEO in Pharmexa says: "In-licensing is an important part of Pharmexa's strategy, and we are very pleased that we now have broad access to Provax®. We recently expanded our license to the PADRE® epitope from Epimmune and signed an agreement with Antigenics concerning the adjuvant QS-21 for use in our HER-2 AutoVac(TM) Protein breast cancer program. Each of these agreements secures us access to technologies that complement and strengthen our proprietary technology platform within immunotherapy."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.